Lento Bio was founded in 2022 by Dr. Kris Barnes with a singular focus: restoring the aging lens. From day one, the company has been built on close collaboration with Ichor Life Sciences, whose CEO Dr. Kelsey Moody and CSO Dr. Aaron Wolfe have served as strategic advisors since inception. Together with a clinical and scientific advisory board spanning ophthalmology, organic chemistry, and biopolymer therapeutics, Lento’s team bridges the full arc from bench research to clinical translation.

Management Team


Kris Barnes
Kris Barnes, PhD
Founder and CEO, Director
Anita Rajamani
Anita Rajamani, PhD
Chief Operating Officer

Scientific & Clinical Advisory Board


Ram Nagaraj
Ram Nagaraj, PhD
Lens and Presbyopia Scientific Advisor
James Frederich
James Frederich, PhD
Director of Medicinal Chemistry
Wesley Jackson
Wesley Jackson, PhD
President & CSO at Valitor, Life Science Startup Launch Advisor
Mark Breazzano
Mark Breazzano, MD, FACS
Associate Professor at Flaum Eye Institute / University of Rochester
Igor Bussel
Igor Bussel, MD, MS, MHA
Ophthalmologist and Professor at UCI School of Medicine
Janet Hurt
Janet Hurt, MPH
Clinical Development Strategy Advisor
Aaron Wolfe
Aaron Wolfe, PhD
Strategic Advisor
(CSO at Ichor Life Sciences)
Steven Feldon
Steven Feldon, MD, MBA
Ophthalmology Business Development Advisor

Scientific & Operational Partnerships


Key contributors to Lento Bio's programs through our partner organizations

Kris Grohn
Kris Grohn, PhD
Scientist, Ichor Life Sciences
Method Development & Analytical Chemistry Lead
Andy Sargrad
Andy Sargrad
Research Associate, Ichor Life Sciences
Program Project Manager, In Vivo Research
Nichole Fish
Nichole Fish
Operations Support Specialist, Ichor Life Sciences
Accounting & Business Operations
Sheila Duong
Sheila Duong
Synthetic Chemist & PhD Candidate
FSU Frederich Laboratory

Board of Directors


Kris Barnes
Kris Barnes, PhD
Founder and CEO, Director
Kelsey Moody
Kelsey Moody, PhD, MBA
Director, Strategic Advisor
(CEO at Ichor Life Sciences)
Houman Hemmati
Houman Hemmati, MD PhD
Director
(Ophthalmology Pharmaceutical Entrepreneur & Executive)
Kenneth Scott
Kenneth Scott
Director, Investor
(Lead, KHL Foundation)

Kris Barnes, PhD

Dr. Barnes’ principal professional interest is to develop therapies to protect valuable human lives against aging and age-related disease. He earned his BS in Biology from SUNY Oswego and his PhD in Neuroscience from Weill Cornell Medicine, after which he was a competitive intelligence consultant in the biotech space with focus on multiple types of chronic diseases including in ophthalmology. He founded Lento Bio at idea-stage in 2022 with the goal of developing novel treatments for chronic aging disorders of the lens, having in the 3 years since developed and patented Lento Bio’s current lead presbyopia asset.

Kris Barnes

Anita Rajamani, PhD

Dr. Rajamani serves as Chief Operating Officer at Lento Bio, where she leads operational strategy and execution. She earned her BS in Biomedical Engineering from Georgia Institute of Technology and her PhD from UC Davis, where her research focused on cardiovascular mechanobiology and lipidomics. Prior to joining Lento Bio, Dr. Rajamani held roles spanning competitive intelligence, clinical evaluation, and new product assessment across the life sciences industry, including positions at Astellas Pharma and Intuitive. She brings a unique combination of scientific rigor and strategic leadership to drive cross-functional initiatives as Lento Bio advances its presbyopia treatment program.

Anita Rajamani

Kelsey Moody, PhD, MBA

Dr. Moody is a process-oriented drug developer and executive who has specialized in the study of aging and aging mechanisms for over a decade. Since 2013, Dr. Moody has successfully built Ichor Life Sciences from a living room start-up into a premier, vertically integrated research organization focused on drug discovery and development for pathways of aging. His work has been published in high impact peer-reviewed journals, including Cell. Dr. Moody holds a PhD in biochemistry and molecular biology from the University of Miami Miller School of Medicine, an MBA in risk management from Concordia University Wisconsin, and a BSc in biochemistry from SUNY Plattsburgh.

Kelsey Moody

Kenneth Scott

Kenneth Scott is a director of and investor in Lento Bio. He leads the KHL Foundation, which is focused on getting new treatments into humans earlier.

Kenneth Scott

Aaron Wolfe, PhD

As a biophysicist with over 15 years of experience, Dr. Aaron Wolfe looks at the world and asks how we can illuminate scientific black boxes as fast as possible. Dr. Wolfe holds a PhD in Structural Biology, Biochemistry, and Biophysics from Syracuse University. Aaron founded Finger Lakes Bio LLC where he licensed a proprietary expression tag allowing for the scaled manufacturing of complex proteins in E. Coli. Finger Lakes Bio was later acquired by Ichor Life Sciences where Aaron became partner and Chief Science Officer. Upon becoming a partner at Ichor, Aaron took part in over $14 million of fundraising across the Ichor portfolio of 7 independent companies.

Aaron Wolfe

Ram Nagaraj, PhD

Dr. Nagaraj is a renowned researcher in lens biochemistry and a former Professor of Ophthalmology at the University of Colorado School of Medicine. Dr. Nagaraj’s educational background includes a Ph.D. in Biochemistry, and he has dedicated his career to investigating the processes that lead to lens aging. His research focuses on protein crosslinking in the lens, which contributes to protein aggregation, insolubilization, light scattering, and the loss of lens accommodation. He has also extensively studied the accumulation of advanced glycation end products (AGEs) in the lens capsule and how they may contribute to secondary cataract formation with age. Currently, Dr. Nagaraj is actively testing novel small molecules aimed at combating AGE-mediated protein crosslinking and restoring lens resilience in aging eyes. His work addresses conditions such as presbyopia by targeting the underlying biochemical causes of lens stiffness and loss of accommodation.

Ram Nagaraj

Janet Hurt, MPH

Janet Hurt, MPH, is a clinical operations and development executive with 35 years of biopharmaceutical experience spanning operational strategy and execution from early- through late-stage development. She has led preparation of key regulatory submissions, including INDs, CTAs, DSURs, Investigator’s Brochures, annual reports, and NDAs, and has directed inspection readiness to ensure compliance with GCP, ICH, and global regulatory standards. Throughout her career, she has built and led high-performing Clinical Operations, Data Management, and Outsourcing functions, delivering global multicenter Phase 1–3 trials across a broad range of therapeutic areas. Most recently, she served as Senior Vice President, Clinical Operations at Accutar Biotechnology.

Janet Hurt

Steven Feldon, MD, MBA

Steven Feldon, M.D., M.B.A. is Emeritus Professor and Chair of Ophthalmology at the University of Rochester, School of Medicine, David & Ilene Flaum Eye Institute. He serves on multiple scientific advisory boards and is a Director on the Board of Excell Partners, a seed venture capital organization in Western NY. As a serial inventor and entrepreneur, he invented and brought to market the Tono-Pen®, the first and among the most popular hand-held electronic devices that measure intraocular pressure for use in glaucoma evaluation.

Steven Feldon

James Frederich, PhD

Dr. Frederich heads an NIH-funded research laboratory at Florida State University that focuses on developing new strategies and tactics to build complex natural products. His laboratory is specifically interested in biologically active structures that modulate protein-protein interactions in vivo. Dr. Frederich received his PhD in synthetic organic chemistry from UC Irvine, and then served as an American Cancer Society Postdoctoral Fellow at UCLA before starting his independent career at Florida State in 2014. To date, his laboratory has raised over $3 million in federal funding to tackle challenging fundamental problems at the interface of chemistry, biology, and medicine.

James Frederich

Houman Hemmati, MD PhD

Dr. Hemmati is a Board-Certified ophthalmologist and an Ophthalmology Biotech & Pharmaceutical Entrepreneur & Executive. Dr. Hemmati received his Ph.D. in Biology from Caltech and completed his postdoctoral fellowship in Chemical Engineering and Drug Delivery at MIT, and is an Adjunct Assistant Clinical Professor of Ophthalmology at USC Keck School of Medicine. He now serves as Chief Medical Affairs Officer at Vyluma, Inc., where he helps lead the development of pharmacological treatments for nearsightedness (myopia) and other refractive eye conditions. Dr. Hemmati has played a key role in the development of innovative ophthalmic therapies, most notably at Allergan, where he served as Director of Clinical Development. During his time there, he was instrumental in the clinical development of Vuity, the recently approved eyedrop treatment for presbyopia. Furthermore, Dr. Hemmati consulted for Viewpoint Therapeutics, a company previously focused on small-molecule therapies targeting lens protein aggregation. His hands-on experience with the clinical development of eyedrop formulations for presbyopia gives him unique insights into the challenges and opportunities in developing effective solutions for this condition.

Houman Hemmati

Wesley Jackson, PhD

Dr. Jackson is President and Chief Scientific Officer at Valitor, an ophthalmic biotech company developing long-acting biopolymer therapies for vision-threatening diseases. He earned his BS from UC Berkeley and his PhD from UC San Francisco, followed by postdoctoral research at the National Institutes of Health. A biotechnology entrepreneur for over 20 years, Dr. Jackson co-founded Valitor and helped in-license its novel protein-biopolymer conjugation platform from UC Berkeley. He has served as principal investigator on nine NIH projects and led Valitor through a $28M Series B financing. His deep experience in ophthalmology drug development, startup strategy, and preclinical-to-clinical translation makes him a key strategic resource as Lento Bio advances its presbyopia treatment program.

Wesley Jackson

Mark Breazzano, MD, FACS

Dr. Mark Breazzano, M.D., F.A.C.S., serves on the LentoBio Scientific Advisory Board. He is a board-certified ophthalmologist at Retina-Vitreous Surgeons of Central New York and serves as Clinical Assistant Professor of Ophthalmology & Visual Sciences at SUNY Upstate Medical University. Dr. Breazzano enjoys a reputation as a talented vitreoretinal physician and surgeon, frequently presenting to national and international audiences. His interests include treatment of endophthalmitis, retinal detachment, subluxated intraocular lenses, and age-related macular degeneration, among other age-related conditions and complications.

Mark Breazzano

Igor Bussel, MD, MS, MHA

Igor Bussel, M.D., M.S., M.H.A is a Clinician-Scientist, Board-Certified Ophthalmologist, and Fellowship-Trained Ophthalmic Surgeon. Before starting a private practice, Dr. Bussel was an attending surgeon and teaching faculty at UCI Gavin Herbert Eye Institute and the Director of the Glaucoma Section at VA Long Beach Hospital. Dr. Bussel earned his medical degree from Rosalind Franklin University of Medicine and Science in Chicago, where he also earned master’s degrees in biomedical science and healthcare administration. He completed his residency in ophthalmology at the University of Pittsburgh School of Medicine and a fellowship in glaucoma and advanced anterior segment surgery at Washington University School of Medicine in St. Louis. He remains an Assistant Clinical Professor at the UCI School of Medicine and has served as a consultant to numerous biotechnology and pharmaceutical companies focused on developing interventions for age-related diseases.

Igor Bussel

Kris Grohn, PhD

Kris Grohn is a Scientist at Ichor Life Sciences with over a decade of experience in key areas of biochemistry relevant to Lento Bio’s work. He leads method development and analytical chemistry efforts for Lento Bio, bringing deep expertise in protein characterization and small molecule analysis. His contributions are critical to the development and quality control of Lento Bio’s therapeutic candidates, ensuring rigorous scientific standards throughout the drug development process.

Kris Grohn

Andy Sargrad

Andy Sargrad is a Research Associate at Ichor Life Sciences with experience across a range of animal models for ocular disease. He serves as Program Project Manager for Lento Bio’s in vivo research, where he performs and oversees technical procedures and data collection. His hands-on expertise with preclinical models and study management ensures the consistent execution and quality of Lento Bio’s animal studies, which are essential for advancing the company’s therapeutic candidates toward clinical development.

Andy Sargrad

Nichole Fish

Nichole is Operations Support Specialist at Ichor Life Sciences. She supports Lento Bio’s accounting and business operations and provides administrative support, helping ensure smooth day-to-day operational execution across the company’s research and business functions.

Nichole Fish

Sheila Duong

Sheila Duong is a synthetic chemist and PhD candidate in Dr. James Frederich’s laboratory at Florida State University. She works on novel compound design and synthesis for Lento Bio, applying her expertise in organic chemistry to create and optimize molecules that target the biochemical processes underlying lens aging. Her work is central to expanding Lento Bio’s pipeline of therapeutic candidates beyond the current lead asset.

Sheila Duong